Publicaciones en colaboración con investigadores/as de Aix-Marseille University (6)

2023

  1. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial

    Journal of Thoracic Oncology, Vol. 18, Núm. 12, pp. 1731-1742

2019

  1. Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2109-2119

2018

  1. Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non–Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care

    Clinical Lung Cancer, Vol. 19, Núm. 6, pp. e823-e830

  2. Second-Line Treatment Options in Non–Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology

    Clinical Lung Cancer, Vol. 19, Núm. 4, pp. 301-314

2017

  1. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III Trials (CheckMate 017 and CheckMate 057)

    Journal of Clinical Oncology, Vol. 35, Núm. 35, pp. 3924-3933

2014

  1. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations

    Clinical Cancer Research, Vol. 20, Núm. 16, pp. 4251-4261